A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure

A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure

BackgroundPathological cardiac hypertrophy is commonly resulted from sustained pressure overload and/or metabolic disorder and eventually leads to heart failure, lacking specific drugs in clinic. Here, we aimed to identify promising anti-hypertrophic drug(s) for heart failure and related metabolic d...

Full description

Bibliographic Details
Main Authors: Zhenya Wang, Wei Shi, Taibo Wu, Tian Peng, Xiaoming Wang, Shuaiyang Liu, Zifeng Yang, Jia Wang, Peng-Long Li, Ruifeng Tian, Ying Hong, Hailong Yang, Lan Bai, Yufeng Hu, Xu Cheng, Hongliang Li, Xiao-Jing Zhang, Zhi-Gang She
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
luteolin
cardiac hypertrophy
heart failure
peroxisome proliferator activated receptor γ
fatty acid metabolism
glucose metabolism
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1130635/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1130635/full

Similar Items